NCT02764125View on ClinicalTrials.gov

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 8, 2016

Primary Completion Date

March 27, 2018

Study Completion Date

March 27, 2018

Conditions

Parkinson's Disease

Interventions

DRUG

Stalevo

levodopa/carbidopa/entacapone

DRUG

levodopa MR

levodopa MR/carbidopa/ODM-104

Trial Locations (4)

1083

Semmelweis Egyetem Neurológiai Klinika, Budapest

20520

Clinical Research Services Turku CRST, Turku

34128

Study Coordinating Investigator, Harleshausen

LV1012

Investigator, Riga

All Listed Sponsors

lead

Orion Corporation, Orion Pharma

INDUSTRY

NCT02764125 - Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC) | Biotech Hunter | Biotech Hunter